Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ascitic complement system in ovarian cancer.

L Bjørge1, J Hakulinen, O K Vintermyr

  • 1Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, FIN-00014 Helsinki, Finland. Line.Bjorge@gades.uib.no

British Journal of Cancer
|February 24, 2005
PubMed
Summary

The complement system in ovarian cancer ascites shows activation but is inhibited, hindering immune surveillance. However, it can be harnessed for antibody-based therapies by neutralizing inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.

Gynecologic oncology·2024
Same author

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Low incidence of severe bacterial infections in hospitalised patients with COVID-19: A population-based registry study.

Infectious diseases (London, England)·2022
Same author

Lipopolysaccharides and outer membrane proteins as main structures involved in complement evasion strategies of non-typhoidal Salmonella strains.

Molecular immunology·2022
Same author

Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection.

Journal of virological methods·2022
Same author

Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1.

Nature communications·2021

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Ovarian cancer frequently spreads intraperitoneally, leading to ascites, which can delay diagnosis and treatment.
  • The complement system is crucial for immune surveillance and antibody-based therapies, potentially offering a cytotoxic effector mechanism.

Purpose of the Study:

  • To characterize the complement system within the ascitic fluid (AF) of ovarian cancer patients.
  • To evaluate the potential of the ascitic complement system as an effector mechanism for intraperitoneal antibody-based therapies.

Main Methods:

  • Assessed hemolytic activity of classical and alternative complement pathways in AF samples.
  • Quantified complement component levels (C3, C4) and activation products (C3a, soluble C5b-9) in AF.
  • Detected complement deposits (C1q, C3, C5b-9) on isolated malignant cells and analyzed complement regulators.

Related Experiment Videos

Main Results:

  • Most AF samples exhibited classical and alternative pathway hemolytic activity, with elevated C3a and soluble C5b-9 indicating in vivo complement activation.
  • Malignant cells showed surface C1q and C3 deposits but lacked the membrane attack complex (MAC), likely due to complement regulator expression (CD46, CD55, CD59).
  • AF contained higher concentrations of soluble complement inhibitors (C1 inhibitor, CD59, CD46, Factor H, FHL-1) than serum.

Conclusions:

  • The complement system in ovarian cancer ascites is activated but its effector functions are suppressed by intrinsic regulators, failing as an effective immune surveillance mechanism.
  • Despite regulatory inhibition, the ascitic complement system can be utilized as an effector mechanism for intraperitoneal antibody-based therapies, particularly if complement regulators are neutralized.